Molecular imaging with 89Zr-PET has been utilized in a phase I study to determine target antigen mesothelin expression, anti-mesothelin antibody tumor uptake, organ distribution at the whole body level, and the relationship between uptake and response to treatment in patients with advanced pancreatic and ovarian cancer. The gene discussed is MSLN; the disease is ovarian cancer.